Compare DexCom, Inc. (DXCM) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Microsoft — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Microsoft trades at $535.07 (market cap $3.88T). The key difference: Microsoft is far larger — about 121.8× DexCom, Inc.'s market cap, and Microsoft pays a 0.75% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Microsoft for 142 Days on average.
| DXCM | MSFT | |
|---|---|---|
Market Cap | $31.86B | $3.88T |
Volume | 3,607,070 | 19,593,392 |
Sector | Health | Technology |
52-Week High | $92.34 | $542.07 |
52-Week Low | $54.84 | $352.83 |
Typical Hold Time | 62 Days | 142 Days |
Enterprise Value | $31.32B | $3.86T |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Microsoft trades at $522.61, down 1.35% today, but maintains strong fundamental performance with consistent earnings beats and robust financial metrics. The stock shows a bullish technical trend with support at $517 and resistance at $530, while fundamentals reveal impressive 36.14% net margins and 34.04% ROE. Recent news highlights Microsoft's AI leadership and cloud computing strength, with analysts maintaining strong buy consensus.
Outlook remains positive with 82% analyst buy ratings and $571.76 consensus target, representing 9.4% upside. Key opportunities include AI integration across products and cloud growth, while risks involve capital expenditure concerns and competitive pressures. The company's strong cash flow generation and debt reduction support long-term shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
